These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 38100005)
81. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. Pickard AS; Gooderham M; Hartz S; Nicolay C J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948 [TBL] [Abstract][Full Text] [Related]
82. Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints. Grutters JP; Joore MA; van der Horst F; Verschuure H; Dreschler WA; Anteunis LJ Qual Life Res; 2007 Oct; 16(8):1439-49. PubMed ID: 17647093 [TBL] [Abstract][Full Text] [Related]
83. Population norms of health-related quality of life in Moscow, Russia: the EQ-5D-5L-based survey. Hołownia-Voloskova M; Tarbastaev A; Golicki D Qual Life Res; 2021 Mar; 30(3):831-840. PubMed ID: 33237551 [TBL] [Abstract][Full Text] [Related]
84. Comparison of EQ-5D-5L, VAS, and SF-6D in Thai Patients on Peritoneal Dialysis. Thaweethamcharoen T; Noparatayaporn P; Sritippayawan S; Aiyasanon N Value Health Reg Issues; 2019 May; 18():59-64. PubMed ID: 30502661 [TBL] [Abstract][Full Text] [Related]
85. Estimating Utility Values for Health States of DFU Patients Using EQ-5D-5L and cTTO. Arab-Zozani M; Safari H; Dori Z; Afshari S; Ameri H; Namiranian N; Hoseini E; Jafari A Int J Low Extrem Wounds; 2022 Mar; 21(1):41-49. PubMed ID: 33939495 [TBL] [Abstract][Full Text] [Related]
86. Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. Joyce VR; Barnett PG; Bayoumi AM; Griffin SC; Kyriakides TC; Yu W; Sundaram V; Holodniy M; Brown ST; Cameron W; Youle M; Sculpher M; Anis AH; Owens DK J Acquir Immune Defic Syndr; 2009 Jan; 50(1):27-36. PubMed ID: 19295332 [TBL] [Abstract][Full Text] [Related]
87. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Longworth L; Yang Y; Young T; Mulhern B; Hernández Alava M; Mukuria C; Rowen D; Tosh J; Tsuchiya A; Evans P; Devianee Keetharuth A; Brazier J Health Technol Assess; 2014 Feb; 18(9):1-224. PubMed ID: 24524660 [TBL] [Abstract][Full Text] [Related]
88. Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression. Abdin E; Chong SA; Seow E; Tan KB; Subramaniam M BMC Psychiatry; 2021 Sep; 21(1):451. PubMed ID: 34517871 [TBL] [Abstract][Full Text] [Related]
89. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States. Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663 [TBL] [Abstract][Full Text] [Related]
90. A cross-country comparison of health-related quality of life in the United States, Sweden, and Norway during the first year of the COVID-19 pandemic. Chen J; Gong CL; Persson U; Gu NY Arch Public Health; 2023 Apr; 81(1):58. PubMed ID: 37081573 [TBL] [Abstract][Full Text] [Related]
91. Health and Utilities in Patients With Gout Under the Care of a Rheumatologist. Spaetgens B; Tran-Duy A; Wijnands JM; van der Linden S; Boonen A Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1128-36. PubMed ID: 25604934 [TBL] [Abstract][Full Text] [Related]
92. How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L. Martin A; Meads D; Griffiths AW; Surr CA Value Health; 2019 Dec; 22(12):1417-1426. PubMed ID: 31806199 [TBL] [Abstract][Full Text] [Related]
93. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA Value Health; 2016; 19(6):834-843. PubMed ID: 27712712 [TBL] [Abstract][Full Text] [Related]
94. Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada. Whitehurst DGT; Mah C; Krebs E; Enns B; Socias ME; Jutras-Aswad D; Le Foll B; Nosyk B; Qual Life Res; 2023 Aug; 32(8):2209-2221. PubMed ID: 37027087 [TBL] [Abstract][Full Text] [Related]
95. Comparison of EQ-5D-5L health state utilities using four country-specific tariffs on a breast cancer patient sample in mainland China. Liu L; Li S; Wang M; Chen G Patient Prefer Adherence; 2017; 11():1049-1056. PubMed ID: 28706443 [TBL] [Abstract][Full Text] [Related]
96. Mapping analysis to predict EQ-5D-5 L utility values based on the Oxford Hip Score (OHS) and Oxford Knee Score (OKS) questionnaires in the Spanish population suffering from lower limb osteoarthritis. Martín-Fernández J; Morey-Montalvo M; Tomás-García N; Martín-Ramos E; Muñoz-García JC; Polentinos-Castro E; Rodríguez-Martínez G; Arenaza JC; García-Pérez L; Magdalena-Armas L; Bilbao A Health Qual Life Outcomes; 2020 Jun; 18(1):184. PubMed ID: 32539838 [TBL] [Abstract][Full Text] [Related]
97. Quality of Life with Late-Onset Pompe Disease: Qualitative Interviews and General Public Utility Estimation in the United Kingdom. Hubig L; Sussex AK; MacCulloch A; Hughes D; Graham R; Morris L; Raza S; Lloyd AJ; Sowinski A; Gallop K J Health Econ Outcomes Res; 2023; 10(1):41-50. PubMed ID: 36883056 [No Abstract] [Full Text] [Related]
98. Mapping EQ-5D utilities to GBD 2010 and GBD 2013 disability weights: results of two pilot studies in Belgium. Maertens de Noordhout C; Devleesschauwer B; Gielens L; Plasmans MHD; Haagsma JA; Speybroeck N Arch Public Health; 2017; 75():6. PubMed ID: 28191312 [TBL] [Abstract][Full Text] [Related]
99. Comparing the self-perceived quality of life of multimorbid patients and the general population using the EQ-5D-3L. N'Goran AA; Déruaz-Luyet A; Haller DM; Zeller A; Rosemann T; Streit S; Herzig L PLoS One; 2017; 12(12):e0188499. PubMed ID: 29261695 [TBL] [Abstract][Full Text] [Related]
100. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]